ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Stock Price Down 2.6% – Time to Sell?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) dropped 2.6% on Thursday . The company traded as low as $49.20 and last traded at $49.41. Approximately 19,727 shares were traded during trading, a decline of 53% from the average daily volume of 41,999 shares. The stock had previously closed at $50.72.

ALPS Medical Breakthroughs ETF Price Performance

The stock’s 50-day moving average is $51.23 and its 200-day moving average is $45.65.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Exencial Wealth Advisors LLC lifted its stake in ALPS Medical Breakthroughs ETF by 3.2% during the fourth quarter. Exencial Wealth Advisors LLC now owns 8,101 shares of the company’s stock valued at $415,000 after purchasing an additional 248 shares during the last quarter. Royal Bank of Canada grew its position in ALPS Medical Breakthroughs ETF by 2.8% in the fourth quarter. Royal Bank of Canada now owns 12,269 shares of the company’s stock worth $628,000 after buying an additional 330 shares during the last quarter. McGuire Investment Group LLC increased its holdings in shares of ALPS Medical Breakthroughs ETF by 5.9% in the fourth quarter. McGuire Investment Group LLC now owns 8,798 shares of the company’s stock valued at $451,000 after buying an additional 488 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of ALPS Medical Breakthroughs ETF in the fourth quarter valued at $26,000. Finally, Griffin Asset Management Inc. lifted its position in shares of ALPS Medical Breakthroughs ETF by 1.9% during the 4th quarter. Griffin Asset Management Inc. now owns 30,699 shares of the company’s stock valued at $1,572,000 after acquiring an additional 564 shares during the last quarter.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.